Stem cell therapy in scleroderma.

Yolanda Braun-Moscovici; Daniel E Furst

doi:10.1097/00002281-200211000-00014

Home/Archive/PubMed

PubMed · 12410096

Stem cell therapy in scleroderma.

Yolanda Braun-Moscovici·Daniel E Furst

View original source ↗Export metadata ↓

Abstract

Scleroderma has a high mortality rate, especially in patients with early diffuse disease and poor prognostic features (such as high skin scores and internal organ involvement). In addition, there is no proven therapy for this disease. Finally, scleroderma has an autoimmune-related pathogenesis, particularly in early illness. In this setting, stem cell therapy is a reasonable potential choice. The rationale behind high-dose immunosuppressive therapy and stem cell transplantation in scleroderma, the regimens used, and the recent data from pilot studies are reviewed. The encouraging data, proper patient selection criteria, and appropriate therapy regimen make controlled studies appropriate, and such studies are currently under way in Europe and are soon to begin in the United States.

Explore related subjects

Dose-Response Relationship, Drug Europe Hematopoietic Stem Cell Transplantation Humans Immunosuppressive Agents Pilot Projects Scleroderma, Systemic Transplantation Conditioning Treatment Outcome Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Yolanda Braun-Moscovici, Daniel E Furst. 2002. Stem cell therapy in scleroderma.. https://doi.org/10.1097/00002281-200211000-00014

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Concise and efficient asymmetric synthesis of (S)-2-ethylphenylpropanoic acid derivatives: dual agonists for human peroxisome proliferator-activated receptor alpha and delta.

Optically active (S)-2-ethylphenylpropanoic acid derivatives, dual agonists for human peroxisome proliferator-activated receptor (PPAR) alpha and delta, were efficiently prepared by using Evan's chiral oxazolidinone technique and reductive amide N-alkylation as key steps.

Dose-Response Relationship, Drug↗

PubMed2005

[How much vitamin B6 is toxic?].

Vitamin B6 (pyridoxine) causes neuropathy at intakes of 1000 mg per day or more, which is about 800 times the daily intake from foods. There have also been occasional reports of toxicity at intakes of 100-300 mg per day. The US authorities set the no-observed-adverse-effect-level at 200 mg per day and the safe upper limit at 100 mg per day. A report of neurotoxicity in 2 patients who had taken 24 mg and 40 mg of vitamin B6 per day respectively, may be coincidence rather than a true toxic effect of such relatively low doses. However, physicians need to remain alert to high intakes of vitamin B6 as a cause of unexplained neuropathy.

Dose-Response Relationship, Drug↗

PubMed2005

Inhibition of drug-resistant HIV-1 by RNA interference.

RNA interference is a powerful tool used to inhibit human immunodeficiency virus type 1 (HIV-1) replication in vitro. Almost all HIV-1 genes have been targets for small interfering RNA (siRNA) molecules, and HIV-1 replication can be specifically and successfully inhibited by this technique. RNA interference has been proposed as an alternative strategy to inhibit replication of drug-resistant viruses that emerge during suboptimal antiretroviral therapy for HIV-1. To investigate specific inhibition of drug-resistant HIV-1 by RNA interference, we designed siRNA molecules that recognize codons 181-188 of the reverse transcriptase (RT) gene of wild-type HIV-1 and HIV-1 carrying the M184V mutation, which confers high-level resistance to the RT inhibitor lamivudine. Using viral variants with single point mutations at codon 184, we measured the impact of these mutations on virus replication. We have demonstrated that siRNA targeting either wild-type HIV-1 or M184V variants inhibits replication of the corresponding virus, but does not influence replication of virus with a mismatch in the targeted region. Combining two effective siRNAs did not show synergistic inhibitory effect on HIV-1 replication. However, a combination of lamivudine and siRNA-M184V was very effective in inhibiting replication of both wild-type and variant M184V viruses in mixed infection experiments. Taken together, these results demonstrate that RNA interference might be useful in the treatment of drug-resistant HIV-1 infection.

Dose-Response Relationship, Drug↗